NEW ORLEANS, March 18, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until March 22, 2016 to file lead plaintiff applications in a securities class action lawsuit against HeartWare International Inc. (Nasdaq:HTWR). Investor losses must relate to purchases of the Company’s securities between June 10, 2014 and January 11, 2016. This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of HeartWare and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by March 22, 2016.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 



